Antonella Giannantoni

Prof. Antonella Giannantoni

Department of Medical and Surgical Sciences and Neurosciences, Functional and Surgical Urology Unit, University of Siena, 53100 Siena, Italy
orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 August 2019 in Toxins
Verified
Journal Article
Open access
PDF file
Antonella GiannantoniAntonella Giannantoni
Antonella Giannantoni
MGMarilena Gubbiotti
Marilena Gubbiotti
VBVittorio Bini
Vittorio Bini
Botulinum neurotoxin A (BoNT/A) appears to be one of the best intravesical treatments for interstitial cystitis/bladder painful syndrome (IC/BPS). We aimed to point out what the evidence is regarding the effects of BoNT/A intravesically injected in patients with IC/BPS. We performed a systematic review of all randomized controlled trials (RCTs) assessing BoNT/A for IC/BPS by using Medline, EMBASE, CINAHL, CENTRAL and MetaRegister of Controlled Trials. Standardized mean differences (SMD) were extracted from the available trials and combined in a meta-analysis applying a random effect model, including heterogeneity of effects. Twelve trials were identified. Significant benefits from BoNT/A injections were detected in: Interstitial Cystitis Symptom Index and Problem Index (ICSI, ICPI) (small to medium effect size: SMD = –0.302; p = 0.007 and –0.430, p = 0.004, respectively); Visual Analog Scale (VAS) for pain and day-time urinary frequency (medium effect size: SMD = –0.576, p < 0.0001 and –0.546, p = 0.013, respectively). A great effect size was detected for post-void residual volume (PVR, SMD = 0.728; p =0.002) although no clinically relevant in most cases. Great heterogeneity was observed in treatments’ methodologies and symptoms assessment. Overall, BoNT/A intravesical injections significantly improve some of the most relevant symptoms affecting IC/BPS patients.

28 November 2021 in Cancers
Verified
Journal Article
Open access
PDF file
Maria Beatrice MorelliMaria Beatrice Morelli
Maria Beatrice Morelli
Consuelo AmantiniConsuelo Amantini
Consuelo Amantini
JVJacopo Adolfo Rossi de Vermandois
Jacopo Adolfo Rossi de Vermandois
MGMarilena Gubbiotti
Marilena Gubbiotti
Antonella GiannantoniAntonella Giannantoni
Antonella Giannantoni
GSGiorgio Santoni
Giorgio Santoni
Background: PD-L1 represents a crucial immune checkpoint molecule in the tumor microenvironment, identified as a key target for cancer immunotherapy. A correlation between PD-L1 and EMT-related genes expression in various human cancers has been suggested. Methods: By ScreenCell filtration, digital droplet PCR and confocal microscopy analysis, we aimed to investigate the expression of PD-L1 and EMT/invasive genes (TWIST1, ZEB1, VIMENTIN, TIMP2) in circulating tumor cells (CTCs) collected from the blood of non-muscle-invasive bladder cancer (NMIBC) patients, assessing the prognostic value of these biomarkers in the disease. Welchs’ test and Mann–Whitney U test, correlation index, Kaplan–Meier, Univariate and Multivariate Cox hazard proportional analysis were used. Results: Higher PD-L1, TIMP2 and VIM mRNA levels were found in pT1 compared to pTa NMIBC. As evaluated by Kaplan–Meier and Univariate and Multivariate Cox analysis, enhancement of PD-L1, TWIST1 and TIMP2 expression reduces the recurrent free survival in NMIBC patients. Conclusions: High PD-L1, TWIST1 and TIMP2 mRNAs mark the recurrent-NMIBC patients and by reducing the RFS represent negative prognostic biomarkers in these patients.

3 July 2019 in Neurourology and Urodynamics
Verified
Journal Article
Closed access
PDF file
MGMarilena Gubbiotti
Marilena Gubbiotti
GBGiulia Balboni
Giulia Balboni
VBVittorio Bini
Vittorio Bini
SESandro Elisei
Sandro Elisei
CBChiara Bedetti
Chiara Bedetti
Antonella GiannantoniAntonella Giannantoni
Antonella Giannantoni

12 March 2022 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
AGAlessandro Giammò
Alessandro Giammò
PGPaolo Geretto
Paolo Geretto
EAEnrico Ammirati
Enrico Ammirati
AMAlberto Manassero
Alberto Manassero
LSLuisella Squintone
Luisella Squintone
PGPaolo Gontero
Paolo Gontero
The aim of the present study is to analyze the outcomes of urethral bulking in the treatment of non-neurogenic female stress and mixed urinary incontinence and to assess predictors of clinical outcomes. We retrospectively included all consecutive patients affected by stress or mixed urinary incontinence and treated with urethral bulking. Outcomes were evaluated via the PGI-I questionnaire and the 24-h pad test. Between January 2010 and January 2020, we treated 216 patients (Bulkamid n = 206; Macro-plastique n = 10). The median age at surgery was 66 years (IQR 55–73.75). The median follow-up was 12 months (IQR 12–24). In total, 23.8% of patients were subjected to prior incontinence surgery, 63.8% of patients were affected by genuine stress urinary incontinence, 36.2% reported mixed urinary incontinence, whereas detrusor overactivity was confirmed in only 24.9%. The dry rate was 32.9%; nevertheless, 69.9% of patients declared themselves “very improved” or “improved” (PGI-I1-2). Low complications were observed, mostly classified as Clavien I. After univariate and multivariate analyses, the only statistically significant independent predictor of “dry” outcome was the 24 h pad test, p < 0.001. Urethral bulking could be proposed with more expectations of success in patients with mild urinary incontinence. Patients affected by moderate–severe incontinence are less likely to obtain clinical success; therefore, they should be carefully counselled about clinical expectations before the procedure.

21 January 2019 in BMC Urology
Verified
Journal Article
Open access
PDF file
MGMarilena Gubbiotti
Marilena Gubbiotti
Antonella GiannantoniAntonella Giannantoni
Antonella Giannantoni
SCSimona Cantaluppi
Simona Cantaluppi
ACAnna Chiara Coluccia
Anna Chiara Coluccia
FGFabio Ghezzi
Fabio Ghezzi
Maurizio SeratiMaurizio Serati
Maurizio Serati
Overactive bladder (OAB) can frequently exert a negative effect on female sexual function. Mirabegron, a β3 receptor agonist, improves OAB symptoms, but there are very few information about its role on female sexual dysfunction (FSD). Aim of the study was to assess the impact of Mirabegron on FSD in women affected by OAB. Fifty sexually active women suffering from idiopathic OAB were included in the study. Patients were assessed by means of a urogynecologic physical examination and were asked to complete the 3-day voiding diary, the International Consultation on Incontinence Questionnaire- Short Form (ICIQ-SF), the Female Sexual Function Index (FSFI) questionnaire and VAS, before and 12 weeks after treatment with Mirabegron. In addition, at the same time points, patients underwent uroflowmetry with the measurement of post- void residual volume (PVR). At baseline all patients were affected by OAB symptoms, with 49/50 patients (98%) presenting with FSD. At 12- weeks follow- up, OAB symptoms improved significantly in all patients, with 59.5% of subjects achieving a complete urinary continence. FSFI Total Score significantly improved in 42/50 patients (84%) from 18.9 ± 4.3 to 21.8 ± 4.5 (p < 0.0001). Sixteen cases (32%) presented with no FSD. Also mean ± SD scores of ICIQ-SF and VAS significantly improved (from 17.1 ± 5 to 7.9 ± 4.8 and from 3.9 ± 1.2 to 6.9 ± 1.2 respectively, p < 0.000). Mirabegron not only is able to control urinary symptoms in women with OAB, but also induces a significant improvement in their sexual life.

22 August 2021 in Neurourology and Urodynamics
Verified
Journal Article
Closed access
PDF file
EREmanuele Rubilotta
Emanuele Rubilotta
MBMatteo Balzarro
Matteo Balzarro
MGMarilena Gubbiotti
Marilena Gubbiotti
CCClara Cerrato
Clara Cerrato
Antonella GiannantoniAntonella Giannantoni
Antonella Giannantoni
AAAlessandro Antonelli
Alessandro Antonelli